Upstream Bio, Inc. (NASDAQ:UPB) Receives $45.25 Consensus Price Target from Analysts

Shares of Upstream Bio, Inc. (NASDAQ:UPB) have been given a consensus recommendation of “Moderate Buy” by the five research firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $45.25.

Several brokerages recently issued reports on UPB. Lifesci Capital began coverage on Upstream Bio in a report on Tuesday, December 2nd. They issued an “outperform” rating and a $43.00 price target on the stock. Evercore ISI initiated coverage on Upstream Bio in a research report on Tuesday, November 18th. They issued an “outperform” rating and a $40.00 target price on the stock. Truist Financial assumed coverage on shares of Upstream Bio in a report on Tuesday, October 14th. They set a “buy” rating and a $47.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Upstream Bio in a report on Wednesday, October 8th. Finally, Mizuho upgraded shares of Upstream Bio to a “strong-buy” rating in a research report on Thursday, December 18th.

Upstream Bio Stock Performance

NASDAQ UPB opened at $30.43 on Thursday. Upstream Bio has a one year low of $5.14 and a one year high of $33.00. The company has a 50-day simple moving average of $25.54 and a 200-day simple moving average of $18.73. The firm has a market capitalization of $1.64 billion, a PE ratio of -16.19 and a beta of 1.83.

Upstream Bio (NASDAQ:UPB) last issued its earnings results on Wednesday, November 5th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.15. Upstream Bio had a negative net margin of 4,366.77% and a negative return on equity of 28.71%. The firm had revenue of $0.68 million for the quarter, compared to analysts’ expectations of $0.65 million. Equities analysts forecast that Upstream Bio will post -4.3 earnings per share for the current year.

Hedge Funds Weigh In On Upstream Bio

Several hedge funds and other institutional investors have recently made changes to their positions in UPB. Woodline Partners LP grew its holdings in Upstream Bio by 7.9% in the 3rd quarter. Woodline Partners LP now owns 602,252 shares of the company’s stock worth $11,328,000 after buying an additional 44,000 shares in the last quarter. Verition Fund Management LLC boosted its position in Upstream Bio by 40.3% during the 3rd quarter. Verition Fund Management LLC now owns 47,001 shares of the company’s stock worth $884,000 after acquiring an additional 13,496 shares during the period. Prelude Capital Management LLC bought a new position in shares of Upstream Bio in the third quarter worth $296,000. Parkman Healthcare Partners LLC increased its holdings in shares of Upstream Bio by 17.9% during the third quarter. Parkman Healthcare Partners LLC now owns 843,502 shares of the company’s stock valued at $15,866,000 after purchasing an additional 127,998 shares during the period. Finally, Millennium Management LLC acquired a new position in shares of Upstream Bio during the third quarter valued at $755,000.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.